Flavie Moreau

771 citations

23 papers · 486 indexed · h-index 11

Co-authors: Wladimir Malaga Catherine Astarie‐Dequeker Christophe Guilhot Charlotte Passemar C. Ladel Carlos Martı́n Hans Guehring Roland Brosch
Topics: Osteoarthritis Treatment and Mechanisms (10 papers)Tuberculosis Research and Epidemiology (7 papers)Mycobacterium research and diagnosis (6 papers)
Cited by: Infectious Diseases Rheumatology Molecular Medicine
Journals: Proceedings of the National Academy of SciencesSHILAP Revista de lepidopterologíaAntimicrobial Agents and Chemotherapy
Partner nations: Germany United States France

In The Last Decade

Flavie Moreau

22 papers receiving 482 citations

Peers

Countries citing papers authored by Flavie Moreau

Since Specialization

Citations

This map shows the geographic impact of Flavie Moreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavie Moreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavie Moreau more than expected).

Fields of papers citing papers by Flavie Moreau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Flavie Moreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavie Moreau. The network helps show where Flavie Moreau may publish in the future.

Co-authorship network of co-authors of Flavie Moreau

This figure shows the co-authorship network connecting the top 25 collaborators of Flavie Moreau. A scholar is included among the top collaborators of Flavie Moreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavie Moreau. Flavie Moreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study 2025 ·Lupus Science & Medicine ·T Witte,Ruth Fernandez‐Ruiz,(unknown),(unknown),Flavie Moreau,(unknown),(unknown),(unknown),Joerg Wenzel	1
2	RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF ENPATORAN, A SMALL MOLECULE TOLL-LIKE RECEPTOR 7/8 INHIBITOR, IN CUTANEOUS LUPUS ERYTHEMATOSUS: RESULTS FROM COHORT A 2025 ·The Journal of Rheumatology ·David R. Pearson,Eric F. Morand,Joerg Wenzel,Richard Furie,Maria Dall’Era,Jorge Sánchez‐Guerrero,Sanjeev Roy,(unknown),Hans Gühring,Flavie Moreau,Victoria P. Werth	3
3	Safety, Tolerability, and Pharmacodynamics of the ADAMTS‐5 Nanobody M6495: Two Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis 2024 ·ACR Open Rheumatology ·Asger Reinstrup Bihlet,(unknown),Kosalaram Goteti,Jesper Sonne,C. Ladel,M.A. Karsdal,Victor Ona,Flavie Moreau,(unknown),Anne‐Christine Bay‐Jensen,Hans Guehring	9
4	Natural mutations in the sensor kinase of the PhoPR two-component regulatory system modulate virulence of ancestor-like tuberculosis bacilli 2023 ·PLoS Pathogens ·Wladimir Malaga,Delphine Payros,(unknown),Wafa Frigui,Fadel Sayes,Alexandre Pawlik,Mickael Orgeur,(unknown),Flavie Moreau,Serge Mazères,Jesús Gonzalo‐Asensio,(unknown),Carlos Martı́n,Catherine Astarie‐Dequeker,Lionel Mourey,Roland Brosch,Christophe Guilhot	5
5	Enpatoran in COVID‐19 pneumonia: Safety and efficacy results from a phase II randomized trial 2023 ·Clinical and Translational Science ·John E. McKinnon,(unknown),Cláudia Murta de Oliveira,Dongzi Yu,(unknown),Flavie Moreau,(unknown),(unknown),Sanjeev Roy,Amy Kao,(unknown)	10
6	1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW) 2022 ·SHILAP Revista de lepidopterología ·Eric F. Morand,Victoria P. Werth,Andrew T. Bender,(unknown),(unknown),Bharat Vaidyanathan,(unknown),Melinda Przetak,Flavie Moreau,(unknown),Sanjeev Roy,David R. Pearson	0
7	Rv0180c contributes to Mycobacterium tuberculosis cell shape and to infectivity in mice and macrophages 2021 ·PLoS Pathogens ·Delphine Payros,Henar Alonso,Wladimir Malaga,(unknown),Serge Mazères,Sébastien Dejean,Sophie Valière,Flavie Moreau,Stéphanie Balor,Alexandre Stella,Lucie Combes‐Soia,Odile Burlet‐Schiltz,Olivier Bouchez,Jérôme Nigou,Catherine Astarie‐Dequeker,Christophe Guilhot	11
8	Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli 2021 ·Nature Microbiology ·Aideen C. Allen,Wladimir Malaga,Cyril Gaudin,(unknown),Flavie Moreau,(unknown),Catherine Astarie‐Dequeker,António Peixoto,Rudy Antoine,Alexandre Pawlik,Wafa Frigui,(unknown),Roland Brosch,Philip Supply,Christophe Guilhot	12
9	Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study 2021 ·Annals of the Rheumatic Diseases ·F. Eckstein,Marc C. Hochberg,Hans Guehring,Flavie Moreau,Victor Ona,Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,(unknown),(unknown),C. Ladel,M. Michaelis,Philip G. Conaghan	73
10	The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial 2021 ·Seminars in Arthritis and Rheumatism ·Hans Guehring,Flavie Moreau,(unknown),C. Ladel,(unknown),Asger Reinstrup Bihlet,W. Wirth,F. Eckstein,Marc C. Hochberg,Philip G. Conaghan	36
11	Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study 2020 ·Osteoarthritis and Cartilage ·F. Eckstein,Marc C. Hochberg,(unknown),Hans Guehring,Flavie Moreau,Victor Ona,Asger Reinstrup Bihlet,I. Byrjalsen,J.R. Andersen,(unknown),(unknown),C. Ladel,M. Michaelis,Philip G. Conaghan	3
12	Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study 2020 ·Osteoarthritis and Cartilage ·Alan Brett,M.A. Bowes,Philip G. Conaghan,C. Ladel,Hans Guehring,Flavie Moreau,F. Eckstein	18
13	Assessment of cartilage markers in synovial fluid from the forward study provide insight to the biphasic effect of sprifermin 2020 ·Osteoarthritis and Cartilage ·Anne‐Christine Bay‐Jensen,Angela A. Manginelli,Flavie Moreau,Yi He,Yunyun Luo,Asger Reinstrup Bihlet,J.R. Andersen,M.A. Karsdal,Hans Guehring,C. Ladel	1
14	FRI0404 SEPERATION OF HIGH AND LOW RESPONSE GROUPS IN OSTEOARTHRITIS USING SERUM CARTILAGE DEGRADATION AND FORMATION MARKERS – A 3 YEAR FOLLOW-UP ON THE FORWARD STUDY TESTING THE EFFICACY OF SPRIFERMIN 2020 ·Annals of the Rheumatic Diseases ·Hans Gühring,Anne‐Christine Bay‐Jensen,Flavie Moreau,J.R. Andersen,Asger Reinstrup Bihlet,M.A. Karsdal	1
15	SAT0647 MRI DATA FROM THE SPRIFERMIN PHASE II FORWARD STUDY: CONFIRMATION OF MANUAL CARTILAGE SEGMENTATION FINDINGS BY AUTOMATED SEGMENTATION 2019 ·Annals of the Rheumatic Diseases ·Alan Brett,M.A. Bowes,Philip G. Conaghan,C. Ladel,(unknown),Hans Gühring,Flavie Moreau,F. Eckstein	2
16	OP0010 CARTILAGE THICKNESS MODIFICATION WITH SPRIFERMIN IN KNEE OSTEOARTHRITIS PATIENTS TRANSLATES INTO SYMPTOMATIC IMPROVEMENT OVER PLACEBO IN PATIENTS AT RISK OF FURTHER STRUCTURAL AND SYMPTOMATIC PROGRESSION: POST-HOC ANALYSIS OF THE PHASE II FORWARD TRIAL 2019 ·Annals of the Rheumatic Diseases ·Hans Gühring,(unknown),Flavie Moreau,(unknown),C. Ladel,W. Wirth,Philip G. Conaghan,F. Eckstein,Marc C. Hochberg	7
17	Study design of a phase I, placebo-controlled, First-in-human trial to assess safety and tolerability, immunogenicity, and pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects 2018 ·Osteoarthritis and Cartilage ·(unknown),Rainer Strotmann,Asger Reinstrup Bihlet,Jesper Sonne,C. Ladel,Flavie Moreau,Hans Guehring	5
18	The Kuvan® Adult Maternal Paediatric European Registry (KAMPER) Multinational Observational Study: Baseline and 1-Year Data in Phenylketonuria Patients Responsive to Sapropterin 2015 ·JIMD Reports ·(unknown),Friedrich K. Trefz,Ania C. Muntau,Florian B. Lagler,Flavie Moreau,Jan Alm,Alberto Burlina,Frank Rutsch,Amaya Bélanger‐Quintana,François Feillet	11
19	Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 2014 ·Proceedings of the National Academy of Sciences ·Jesús Gonzalo‐Asensio,Wladimir Malaga,Alexandre Pawlik,Catherine Astarie‐Dequeker,Charlotte Passemar,Flavie Moreau,Françoise Laval,Mamadou Daffé,Carlos Martı́n,Roland Brosch,Christophe Guilhot	137
20	Multiple deletions in the polyketide synthase gene repertoire ofMycobacterium tuberculosisreveal functional overlap of cell envelope lipids in host-pathogen interactions 2013 ·Cellular Microbiology ·Charlotte Passemar,Ainhoa Arbués,Wladimir Malaga,Ingrid Mercier,Flavie Moreau,Laurence Lepourry,Olivier Neyrolles,Christophe Guilhot,Catherine Astarie‐Dequeker	56

About Flavie Moreau

Flavie Moreau is a scholar working on Rheumatology, Infectious Diseases and Rehabilitation, having authored 23 papers that have together received 486 indexed citations. Recurring topics across this work include Osteoarthritis Treatment and Mechanisms (10 papers), Tuberculosis Research and Epidemiology (7 papers) and Mycobacterium research and diagnosis (6 papers). The work is most often cited by research in Infectious Diseases (249 citations), Rheumatology (132 citations) and Molecular Medicine (33 citations). Flavie Moreau has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Wladimir Malaga, Catherine Astarie‐Dequeker, Christophe Guilhot, Charlotte Passemar, C. Ladel, Carlos Martı́n, Hans Guehring, Roland Brosch, Alexandre Pawlik and F. Eckstein. Their work appears in journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact